Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Tipo de estudio
Intervalo de año de publicación
1.
Immunology ; 129(4): 482-95, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20002787

RESUMEN

The lectin pathway of complement is activated upon binding of mannan-binding lectin (MBL) or ficolins (FCNs) to their targets. Upon recognition of targets, the MBL-and FCN-associated serine proteases (MASPs) are activated, allowing them to generate the C3 convertase C4b2a. Recent findings indicate that the MASPs also activate components of the coagulation system. We have previously shown that MASP-1 has thrombin-like activity whereby it cleaves and activates fibrinogen and factor XIII. MASP-2 has factor Xa-like activity and activates prothrombin through cleavage to form thrombin. We now report that purified L-FCN-MASPs complexes, bound from serum to N-acetylcysteine-Sepharose, or MBL-MASPs complexes, bound to mannan-agarose, generate clots when incubated with calcified plasma or purified fibrinogen and factor XIII. Plasmin digestion of the clot and analysis using anti-D-dimer antibodies revealed that the clot was made up of fibrin and was similar to that generated by thrombin in normal human plasma. Fibrinopeptides A and B (FPA and FPB, respectively) were released after fibrinogen cleavage by L-FCN-MASPs complexes captured on N-acetylcysteine-Sepharose. Studies of inhibition of fibrinopeptide release indicated that the dominant pathway for clotting catalysed by the MASPs is via MASP-2 and prothrombin activation, as hirudin, a thrombin inhibitor that does not inhibit MASP-1 and MASP-2, substantially inhibits fibrinopeptide release. In the light of their potent chemoattractant effects on neutrophil and fibroblast recruitment, the MASP-mediated release of FPA and FPB may play a role in early immune activation. Additionally, MASP-catalysed deposition and polymerization of fibrin on the surface of micro-organisms may be protective by limiting the dissemination of infection.


Asunto(s)
Coagulación Sanguínea/fisiología , Fibrina/metabolismo , Serina Proteasas Asociadas a la Proteína de Unión a la Manosa/metabolismo , Acetilcisteína/inmunología , Coagulación Sanguínea/inmunología , Fibrinopéptido A/antagonistas & inhibidores , Fibrinopéptido A/inmunología , Fibrinopéptido B/antagonistas & inhibidores , Fibrinopéptido B/inmunología , Hirudinas/farmacología , Humanos , Protrombina/inmunología , Sefarosa/inmunología
2.
Thromb Haemost ; 94(6): 1236-44, 2005 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-16411400

RESUMEN

Tissue factor (TF), the main initiator of blood coagulation, contributes to the manifestation of disseminated intravascular coagulation following septic shock in meningococcal infection. Since a direct relationship between disease severity and lipopolysaccharide (LPS) concentration in the circulation has been shown, we hypothesized that the procoagulant and cytotoxic effects of endotoxin also in vitro were related to its concentration. In vitro studies, however, have frequently used much higher LPS concentrations than those observed in clinical samples. Using elutriation-purified human monocytes, we observed that LPS up to 1000 ng/ml exerted a concentration-dependent increase in TF activity (tenase activity, fibrin formation in plasma). Although there was a dose-dependent increase in TF activity, there was not a concomitant increase in TF expression at LPS concentrations above 1 ng/ml (flow cytometry, Western blotting, TF mRNA). Flow cytometry revealed that this discrepancy between TF activity and TF expression at endotoxin concentrations above 1 ng/ml, coincided with an LPS dose-dependent increase in cell surface phosphatidylserine (PS), considered to promote coagulation. The increased PS expression was associated with an increased number of 7-AAD-positive cells indicating cell death. We conclude that enhancement of monocyte procoagulant activity in vitro by high concentrations of LPS may result from increased PS exposure due to apoptosis and necrosis. Therefore, the LPS concentrations used to examine monocyte procoagulant activity in vitro, should be carefully chosen.


Asunto(s)
Monocitos/enzimología , ARN Mensajero/metabolismo , Tromboplastina/metabolismo , Anexina A5/farmacología , Anticuerpos Monoclonales , Apoptosis , Coagulación Sanguínea/efectos de los fármacos , Células Cultivadas , Cisteína Endopeptidasas/metabolismo , Relación Dosis-Respuesta a Droga , Fibrinopéptido A/antagonistas & inhibidores , Fibrinopéptido A/metabolismo , Humanos , Lipopolisacáridos/farmacología , Monocitos/efectos de los fármacos , Necrosis , Proteínas de Neoplasias/metabolismo , Fosfatidilserinas/antagonistas & inhibidores , Fosfatidilserinas/metabolismo , Tromboplastina/genética , Tromboplastina/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA